Far more than any other type of illness, mental disorders are subject to negative judgments and stigmatization. Many patients have to cope with the often devastating effects of their condition and ...
ClearBridge Investments, an investment management company, released its “ClearBridge SMID Cap Growth Strategy” second quarter 2023 investor letter. A copy of the same can be downloaded here. The ...
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological ...
Shares of clinical-stage biotech Karuna Therapeutics (NASDAQ: KRTX) are down by a hefty 10% through the first four days of trading this week, according to data from S&P Global Market Intelligence.
Karuna Therapeutics is developing a novel product, KarXT, to treat psychoses related to Alzheimer's and schizophrenia. The product targets muscarinic receptors in an agonist/antagonist combination.
Miller Value Partners, an investment management firm, published its “Miller Opportunity Trust Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. During the second ...
Karuna's experimental schizophrenia medicine, KarXT, hit the mark in a pivotal-stage trial. The company said it plans to file for the drug's regulatory approval by mid-2023. If approved, KarXT ought ...
The clinical-stage biopharmaceutical company announced really great phase 2 results for its lead pipeline candidate. Shares of Karuna Therapeutics (NASDAQ:KRTX) had skyrocketed 233.1% higher as of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback